Sencure
integrated biosensor
technology

Sencure is a company based in Enschede, the Netherlands and was founded in 2021. Originally, the company was named ItoM Medical, a division of the chip developer “Semiconductors Ideas to the Market (ItoM)”.

This company brought two worlds together. Experienced, highly qualified chip designers from the semiconductor world and experts from the Medical Device world with a fascination for the measurement of electrophysiological parameters on the human body.

Sencure develops chips that helps you measure electrophysiological parameters on the human body in innovative ways. The goal is to have as little influence on a patient’s daily life as possible, combined with a maximum impact on the patient’s life. Sencure bridges the gap between compliance and the best solutions for wearable health.

We invested in Secure from our Evergreen Fund.

Our news

9 April, 2026

819 Capital Partners invests in Wolk

Deventer, 9 April 2026 - Dutch company Wolk has raised €1.75 million to accelerate the deployment of its smart hip airbag in elderly care. The investment round was led by 819 Capital Partners, through 819 Seed Fund I, and the Innovatiefonds Ouderenzorg of CbusineZ (CZ), with participation from Nivogé, Catalyst Impact Investment Club, and several angel investors. Each year in the Netherlands, approximately 120,000 elderly people end up in the emergency department after a fall....

Continue reading
6 March, 2026

819 Capital Partners acquires key assets of Lead Pharma, enabling continuation of operations

Deventer, 6 March 2026 - 819 Capital Partners has acquired the key assets of Lead Pharma, thereby realizing a continuation based on the company’s patent portfolio and associated research programs. The transaction includes intellectual property rights, research data, and selected development programs. Lead Pharma develops innovative small-molecule medicines for the treatment of cancer and autoimmune diseases. Over the past years, the company built a strong research platform and multiple drug candidates, collaborating with international pharmaceutical companies...

Continue reading